As per the terms of the agreement, the MyPRS test will be performed at Signal Genetics’ laboratory based in Little Rock, Arkansas and the test results will be incorporated into NeoGenomics’ test reports and provided to their customers along with other ancillary diagnostic tests.
MyPRS analyzes and applies a proprietary algorithm to a defined number of relevant genes to determine the gene expression profile associated with the patient’s condition.
NeoGenomics chairman and CEO Douglas VanOort said their new partnership with Signal Genetics provides access to new prognostic marker for patients with Multiple Myeloma and complements their strategy of bringing novel products to their customers.
"The agreement also provides NeoGenomics a right of first negotiation to market any genomic and transcriptomic-based diagnostic tests developed and/or introduced by Signal in the future to pathologists and hospital-based oncologists/hematologists," VanOort said.
